Condition

mCRPC (Metastatic Castration-resistant Prostate Cancer) clinical trials and research

• 14Clinical trials
• 1New in 30 days
• 6Countries

Newest mCRPC (Metastatic Castration-resistant Prostate Cancer) clinical trials

All recruiting trials (14)

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• AKY-2519 (B7‑H3 targeted radioligand) for metastatic castration‑resistant prostate cancer

  This trial tests whether AKY‑2519, a B7‑H3–targeted radioactive medicine used for imaging and treatment, is safe and can shrink tumors in men with metastatic castration‑resistant prostate cancer, including those who have had prior 177Lu‑PSMA‑617.

  Recruiting at 8 sites Phase 1 Aktis Oncology, Inc. · Irvine, California and 7 other locations · NCT07581184

• SHR-1701 plus focused stereotactic radiation for metastatic castration‑resistant prostate cancer

  This study will test whether adding the immune drug SHR‑1701 to focused stereotactic body radiotherapy (SBRT) can help men with metastatic castration‑resistant prostate cancer who have progressed after next‑generation hormone therapy.

  Recruiting at 3 sites Phase 2 Fudan University · Fujian and 2 other locations · NCT07451795

• Four-timepoint PET scans with three tracers to map differences between prostate cancer metastases

  This will test whether repeating PET scans with three different tracers can map active, treatment‑resistant versus treatment‑sensitive metastases in men with metastatic castration‑resistant prostate cancer who have at least three metastases.

  Recruiting CHU de Quebec-Universite Laval · Québec, Quebec · NCT07302763

• MHB048C treatment for advanced solid tumors, including metastatic castration‑resistant prostate cancer

  This study will test whether the experimental drug MHB048C is safe and shows signs of benefit in adults with advanced solid tumors, including metastatic castration‑resistant prostate cancer.

  Recruiting Phase 1/2 Minghui Pharmaceutical (Hangzhou) Ltd · Shanghai, Shanghai Municipality · NCT07192120

• KTX-2001 (alone and with darolutamide) for men with metastatic castration‑resistant prostate cancer

  This trial tests whether KTX-2001, by itself and combined with darolutamide, can help men whose prostate cancer has spread and stopped responding to hormone therapies.

  Recruiting at 13 sites Phase 1 K36 Therapeutics, Inc. · San Francisco, California and 12 other locations · NCT07103018

• Talazoparib with or without enzalutamide for people with HRR-mutant mCRPC after abiraterone

  This will see if adding enzalutamide to talazoparib, or using talazoparib alone, can slow cancer progression in people with HRR-mutant metastatic castration-resistant prostate cancer who have already taken abiraterone.

  Recruiting at 8 sites Phase 2 Prostate Cancer Clinical Trials Consortium · Duarte, California and 7 other locations · NCT06844383

• Testing ACE-232 for advanced prostate cancer treatment

  This study is testing a new treatment called ACE-232 to see if it is safe and effective for people with advanced prostate cancer that has not responded to other therapies.

  Recruiting at 8 sites Phase 1 Acerand Therapeutics Limited · La Jolla, California and 12 other locations · NCT06801236

• Evaluating Pocenbrodib for advanced prostate cancer treatment

  This study is testing a new drug called Pocenbrodib, alone and with other treatments, to see if it can help people with advanced prostate cancer who haven't responded to previous therapies.

  Recruiting at 19 sites Phase 1/2 Pathos AI, Inc. · Fountain Valley, California and 18 other locations · NCT06785636

• Treatment of advanced prostate cancer with XNW5004 and enzalutamide

  This study tests if combining the drugs XNW5004 and enzalutamide can help men with advanced prostate cancer that hasn't responded to other hormone treatments.

  Recruiting at 2 sites Phase 1/2 Evopoint Biosciences Inc. · Jinan, Shandong and 1 other locations · NCT06702995

• Combination of Gedatolisib and Darolutamide for Advanced Prostate Cancer

  This study is testing a new combination of two drugs, gedatolisib and darolutamide, to see if they can help men with advanced prostate cancer feel better and improve their treatment outcomes.

  Recruiting at 5 sites Phase 1/2 Celcuity Inc · Detroit, Michigan and 12 other locations · NCT06190899

• Evaluating the safety of a new treatment for certain cancer types

  This study is testing a new treatment for certain types of cancer to see if it's safe for adults with recurrent or metastatic tumors.

  Recruiting at 4 sites Phase 1 Orano Med LLC · Chicago, Illinois and 7 other locations · NCT05283330

Related topics

Quick answers

How many mCRPC (Metastatic Castration-resistant Prostate Cancer) clinical trials are recruiting right now?

14, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in United States (10 trials), China (4 trials), France (1 trial), Spain (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 7, Phase 1/2: 4, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →